http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104231080-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2014-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104231080-B |
| titleOfInvention | Human anti-human interleukin-17 A single-chain antibody |
| abstract | Human anti-human interleukin-17 A single-chain antibody, the invention belongs to genetic engineering antibody technical fields, and in particular to genetic engineering design, expresses the human antibody segment for having special affinity with hIL 17 A(IL-17A) at screening.This genetic engineering antibody segment is joined end to end the heavy chain region of antibody and light chain area by one section of flexible connection segment.The present invention obtains the antibody fragment for having Specific adsorption ability to IL-17A by the building natural phage antibody library of large capacity, by Biopanning.The antibody fragment is built into full length antibody, by being able to suppress reaction of the IL-17A to human fibrosarcoma cell HT1080 release interleukin 6 (IL-6) after eukaryotic expression system affinity purification.Antibody fragment of the invention can be used for detecting and treating rheumatoid arthritis. |
| priorityDate | 2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 199.